Civica, Inc. announces that Ned McCoy, currently Civica’s Chief Operating Officer, will succeed Martin VanTrieste as Civica’s President and Chief Executive Officer, effective June 1. VanTrieste will remain an advisor to the Company and continue serving on Civica’s Board of Directors. As part of this transition, McCoy will also join the Civica Board of Directors on June 1. “Martin’s decision to come out of retirement four years ago to help us shape and launch Civica was critical to bringing together diverse stakeholders to create a more reliable and affordable approach to generic medicines,” said Dan Liljenquist, Chairman of the Board of Directors of Civica. “From leading the development of Civica’s future essential medicines manufacturing facility to executing numerous pivotal partnership agreements and, most recently, pioneering Civica’s initiative to manufacture and distribute affordable insulin, Martin’s impact will be felt for decades to come. We’re thrilled Martin will continue serving on our Board of Directors and will help guide the Civica team to build on the many successes during his tenure.”
VanTrieste commented, “It has been an honor to lead Civica and witness firsthand how our organization has improved so many lives – providing enough essential medicine to help treat over 30 million patients to date. Our team’s dedication and passion for building an innovative, transformative generic medication model constantly inspires me. I look forward to continuing to be a part of Civica as a member of the Board and supporting Ned as he takes on this exciting role.” McCoy has provided day-to-day oversight for Civica’s growing manufacturing efforts, including the building of Civica’s state-of-the-art essential medicines manufacturing facility in Petersburg, VA, expected to be operational in early 2024.
McCoy has led efforts to secure manufacturing partnerships for over 60 sterile injectable medications that hospitals use daily, helping Civica supply essential medicines and address chronic drug shortages, unpredictable price inflation, and predatory pricing. He has also been deeply involved with Civica’s commercial team and stakeholders, ensuring hospitals have the medicines they need when they need them. Most recently, McCoy orchestrated the partnership with Civica’s affordable insulin development partner, GeneSys Biologics, with the plan to bring Civica biosimilar insulins to market beginning in 2024. Prior to Civica, McCoy served at Abbott for 32 years, where he led teams in Hospital Products, Pharmaceutical Products (now AbbVie), Nutrition and Corporate Mergers and Acquisitions. McCoy received his Bachelor and Master of Science degrees in Chemical Engineering from North Carolina State University.
Liljenquist continued, “On behalf of the Board, we’re thrilled that Ned will take on this new role, leveraging his strong track record of leading companies to significant growth and executing complementary partnerships. I, and the entire Board, have complete confidence that he will further build on Civica’s important work to serve even more patients and transform the medication landscape.” McCoy commented, “I am honored to serve as the next CEO of Civica and continue our pivotal work of delivering quality generic medications that are available and affordable to everyone. Through much of my time at Civica, I have had the privilege of leading Civica’s operations, including helping to secure successful, long-term manufacturing partnerships and execute the building of our own manufacturing facility. I look forward continuing to work with our talented team and furthering our culture of innovation, excellence and dedication to improving patient lives with a new model for generic hospital and prescription medicines.”
Civica, Inc. (Civica, Civica Rx) is a nonprofit generic pharmaceutical company. Civica was created by hospital systems and philanthropies in 2018 to reduce and prevent chronic drug shortages in hospitals and the unpredictable price spikes that often accompany them. Its mission is to make quality generic medicines accessible and affordable to everyone. Civica has ensured stable and predictable supplies – and fair pricing – of nearly 60 different quality generic medications to date. Most recently, Civica and its outpatient arm, CivicaScript, announced plans to develop, manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin beginning in 2024.
Today Civica is governed by leading hospital systems (CommonSpirit Health, HCA Healthcare, Intermountain Healthcare, Kaiser Permanente, Mayo Clinic, Memorial Hermann, Providence, SSM Health, and Trinity Health), representatives of the payer community (Blue Cross of Idaho and Blue Cross Blue Shield Association), and philanthropies committed to improving healthcare (Gary and Mary West Foundation, Laura and John Arnold Foundation, and Peterson Center on Healthcare).
Hospital advisors—doctors and pharmacists—prioritize the essential medicines Civica provides for use in acute and critical care, emergency rooms, and surgery.